Revenue Performance - Total revenues for Q2 2024 were $4,839 million, approximately flat compared to Q2 2023, with a 1% organic growth [151]. - Sales of services increased by 2% or $28 million, while sales of products decreased by 1% or $6 million [151]. - Imaging segment revenues were $2,596 million, a decrease of 1% or $24 million, impacted by lower volume in China and unfavorable foreign currency effects [152]. - Ultrasound segment revenues were $823 million, down 2% or $16 million, primarily due to lower sales volume in China [152]. - Patient Care Solutions (PCS) segment revenues were $772 million, flat compared to the prior year, with 1% organic growth [152]. - Pharmaceutical Diagnostics (PDx) segment revenues grew by 12% or $71 million, driven by volume growth and new product introductions [152]. - Revenues from the US and Canada (USCAN) increased by 5% or $104 million, with growth across all segments [152]. - Revenues from the China region decreased by 18% or $131 million, affected by delayed stimulus and ongoing anti-corruption campaigns [152]. - Total revenues for the six months ended June 30, 2024, were $9,489 million, flat compared to the prior year [154]. - Total revenues for the three months ended June 30, 2024, were $4,839 million, a slight increase of 1% compared to the same period in 2023 [176]. - Organic revenue for the six months ended June 30, 2024, was $9,565 million, remaining stable compared to $9,524 million in 2023 [176]. Income and Earnings - Operating income for the three months ended June 30, 2024, was $608 million, a 7% increase from $570 million in the same period of 2023 [156]. - Net income attributable to GE HealthCare for the three months ended June 30, 2024, was $428 million, reflecting a 2% increase from $418 million in the prior year [156]. - Adjusted EBIT for the three months ended June 30, 2024, was $742 million, a 4% increase from $711 million in the same period of 2023 [156]. - Adjusted net income for the six months ended June 30, 2024, was $872 million, an 8% increase from $807 million in the prior year [163]. - Adjusted net income for the three months ended June 30, 2024, was $459 million, reflecting a 10% increase from $419 million in 2023 [183]. - Adjusted earnings per share for the three months ended June 30, 2024, was $1.00, up from $0.92 in 2023, representing an increase of 9% [185]. - The net income margin for the three months ended June 30, 2024, improved to 8.9%, up 20 basis points from 8.7% in 2023 [180]. Expenses and Investments - R&D investments increased by $29 million, contributing to a rise in R&D as a percentage of total revenues by 60 basis points [160]. - Total operating expenses increased by $25 million, with SG&A expenses decreasing by $5 million due to cost-saving initiatives [160]. - Cash used for capital expenditures was $209 million for the six months ended June 30, 2024, primarily for manufacturing capacity expansion and new product introductions [199]. Cash Flow and Debt - Free cash flow for the six months ended June 30, 2024, was $92 million, a decrease of 51% from $189 million in 2023, driven by a 25% decline in cash from operating activities [189][198]. - Cash generated from operating activities for the six months ended June 30, 2024, was $300 million, down from $401 million in 2023, with net income of $823 million in 2024 compared to $816 million in 2023 [193][194]. - Cash used for investing activities in the six months ended June 30, 2024, was $537 million, including $259 million for the acquisition of MIM Software Inc. and $209 million for capital expenditures [195][196]. - Total debt as of June 30, 2024, was $9,240 million, a decrease from $9,442 million at the end of 2023, primarily due to a $150 million repayment of the Term Loan Facility [202]. - The company had $2,015 million in cash, cash equivalents, and restricted cash as of June 30, 2024, along with access to $3,500 million in revolving credit facilities [191][204]. - The weighted average interest rate for the company's notes and credit facilities for the six months ended June 30, 2024, was 6.08% [203]. - The company plans to continue relying on capital markets and expects to have access to credit facilities to fund operations, with current credit ratings of Baa2 from Moody's, BBB from S&P, and BBB from Fitch [206][207]. Segment Performance - Imaging Segment EBIT was $526 million, an increase of $57 million due to cost productivity and an increase in price, partially offset by cost inflation [175]. - Ultrasound Segment EBIT was $360 million, a decrease of $38 million due to cost inflation and a decrease in sales volume, particularly in China [175]. - PDx Segment EBIT was $378 million, an increase of $71 million due to growth in sales volume, an increase in price, and cost productivity, partially offset by cost inflation and investments [175]. - Imaging segment revenues were $5,062 million, a decrease of 1% or $54 million compared to the prior year, impacted by unfavorable foreign currency effects [156]. - USCAN revenues increased by 3% or $114 million to $4,336 million, supported by growth in PDx and Imaging revenues [156]. Geopolitical and Market Conditions - The company continues to monitor the impact of geopolitical factors, including the Russia-Ukraine conflict and market conditions in China [140]. - Remaining Performance Obligations (RPO) as of June 30, 2024, decreased by 1% to $14,531 million from $14,655 million as of December 31, 2023, primarily due to fulfillment and cancellations outpacing new contracts [155]. - The company experienced a significant outflow of $820 million from changes in assets and liabilities in the first half of 2024, mainly due to compensation and benefit payments and inventory build [193].

Exhibit 99 GE HealthCare reports second quarter 2024 financial results Chicago, IL – July 31, 2024 – GE HealthCare (Nasdaq: GEHC) today reported financial results for the second quarter ended June 30, 2024. GE HealthCare President and CEO Peter Arduini said, "In the second quarter, we delivered year-over-year sales growth and margin expansion despite headwinds in the China market. We also reported solid orders growth with particular strength in the U.S., as healthcare systems invest in technologies that enh ...

Core Viewpoint - GE HealthCare Technologies Inc. (GEHC) is expected to report second-quarter 2024 results, with a focus on revenue growth driven by strong demand in imaging and pharmaceutical diagnostics, despite challenges in sales volume and macroeconomic conditions [15][8]. Group 1: Revenue Growth and Product Development - Imaging demand remains healthy, particularly in Molecular Imaging, Computed Tomography, and Magnetic Resonance, contributing to top-line growth [2]. - The company completed the acquisition of MIM Software in April, enhancing its product portfolio with new offerings likely to generate additional revenue [2]. - The Pharmaceutical Diagnostics business is anticipated to show strong organic revenue growth due to favorable pricing and recovery in global elective procedures [3]. Group 2: Financial Estimates - The Zacks Consensus Estimate for revenues is projected at $4.89 billion, indicating a year-over-year growth of 1.5% [4]. - The earnings per share estimate is set at 97 cents, reflecting a 5.4% improvement from the previous year [19]. Group 3: Market Performance and Challenges - GEHC's shares have experienced a 25.3% increase year to date, although the company faced lower sales volumes in the second quarter [6][8]. - The Ultrasound business is expected to benefit from the launch of the LOGIQ portfolio and AI software, which may enhance workflow for urologists [9][17]. - Despite strong commercial performance, the company may be impacted by a challenging macroeconomic environment and currency headwinds [18]. Group 4: Segment Performance - The Imaging business is projected to benefit from healthcare providers' investments in capacity, with strong demand for surgical procedures driving imaging needs [25]. - The Patient Care Solutions segment may see organic revenue decline due to unfavorable volume, although improved pricing could provide some offset [27]. - Recent product launches, including the SIGNA MAGNUS MR scanner and Voluson Signature ultrasound systems, are expected to support growth in imaging and patient care solutions [26].

Considering the aging baby boomer population, spending trends can only rise from current levels. In particular, Medicare spending will experience a surge as more boomers enroll. Moreover, spending on physician and clinical services, pharmaceuticals and medical devices keeps rising. This medical device maker has a revolutionary product for the heart health diagnostic market. iRhythm Technologies (NASDAQ:IRTC) offers a cardiac monitoring solution, Zio XT, for heart rhythm monitoring, enabling the detection of ...

GE HealthCare Technologies (GEHC) recently announced that it has entered into an agreement to acquire Intelligent Ultrasound Group PLC's (Intelligent Ultrasound) clinical artificial intelligence (AI) software business for a total consideration of approximately $51 million. With integrated AI-driven picture analysis tools, Intelligent Ultrasound is a leader in making ultrasound more intelligent and effective. With the acquisition of the business, GE HealthCare intends to integrate the technology solutions th ...

As part of HDR brachytherapy, radioactive sources are implanted by needles into the prostate gland to treat prostate cancer. Clinicians typically design these operations using ultrasound or computed tomography (CT) imaging. Critical structural toxicity can be decreased by using MRI in the planning of brachytherapy treatments. MIM Symphony HDR Prostate stands out in the market by correcting MRI orientation and offering MRI guidance during HDR prostate procedures. In April 2024, GE Healthcare announced the cl ...

GE Healthcare Technologies, Inc. (GEHC) , in collaboration with the University of Cincinnati (UC), UC Health, and Cincinnati Children's, has announced a cutting-edge initiative to accelerate MRI innovation. This collaboration will provide a well-established MRI Research and Development (R&D) center of excellence on UC's medical campus, enabling direct interaction between clinical investigators and GE HealthCare scientists. The initiative is supported by an R&D grant from JobsOhio, aimed at boosting engineer ...

Core Insights - GE HealthCare, University of Cincinnati, UC Health, and Cincinnati Children's are collaborating to establish a new MRI Research and Development center aimed at accelerating MRI innovation [1][2][10] - The collaboration will leverage the strengths of both industry and academia to develop next-generation MRI technologies tailored for adult and pediatric patients [10][11] Company and Industry Overview - GE HealthCare has a significant presence in Ohio, including an MRI RF coil R&D and manufacturing facility in Aurora, which produces the award-winning AIR™ Coils that enhance patient comfort and image quality [2][11] - Cincinnati Children's is recognized as the top children's hospital in the U.S. and has a strong focus on research, with nearly one-third of its staff engaged in research activities [5][6] - The University of Cincinnati is a leading public research university with a robust academic health center and a commitment to advancing imaging science [6][7] Collaboration Details - The new R&D center will focus on developing MRI hardware and software that meet unique clinical needs, supported by a grant from JobsOhio to foster job growth in engineering and manufacturing [10][11] - The center will house GE HealthCare's advanced 3.0T wide-bore MRI scanner, the SIGNA™ Premier, which incorporates innovative hardware and AI software technologies to improve imaging capabilities [12][13] Economic Impact - The collaboration is expected to enhance the Cincinnati Innovation District, demonstrating Ohio's leadership in healthcare innovation and improving patient outcomes [11][13] - JobsOhio plays a crucial role in supporting this initiative, aiming to attract talent and foster growth in competitive industry sectors [8][10]

Core Insights - GE HealthCare Technologies Inc. has installed its latest Allia Image Guided System (IGS) Pulse at Heart Hospital of New Mexico, marking the first installation in the U.S. This system aims to enhance image quality and workflow for diagnosing and treating cardiovascular diseases (CVDs) [1][12]. Company Developments - The installation of the Allia IGS Pulse system is expected to strengthen GE HealthCare's position in the CVD treatment market, which is significant given that heart disease has been the leading cause of death in the U.S. for decades, affecting nearly 48.6% of individuals over 20 years old [2][12]. - HHNM, as New Mexico's only hospital dedicated to heart care, anticipates providing innovative treatment options and keeping patients close to home [3]. - GE HealthCare has also entered an agreement with Salud Digna to deploy digital solutions aimed at improving care efficiency across various imaging systems in Mexico [5]. Market Insights - The global electrophysiology market, relevant to GE HealthCare's offerings, was valued at $8.2 billion in 2023 and is projected to reach $15.1 billion by 2028, growing at a CAGR of 13% due to the rising prevalence of CVDs and technological advancements [4]. - The collaboration with HHNM is expected to address healthcare challenges and enhance patient and provider experiences [12]. Performance Metrics - GE HealthCare's shares have increased by 1.6% over the past year, contrasting with a 26.4% decline in the industry, while the S&P 500 has grown by 26.1% during the same period [16].

Company Overview - OmnifyXR is currently available exclusively with GE HealthCare interventional X-ray systems, enhancing GE HealthCare's position in the global interventional radiology market [1] - The latest installation and clinical cases of OmnifyXR at North Star Vascular and Interventional in Minneapolis mark a significant milestone for GE HealthCare [16] Significance of the Announcement - Image-guided therapy is rapidly evolving, addressing conditions like cancer and cardiovascular diseases with minimal surgical intervention, but practitioners face challenges such as positioning restrictions and workspace adjustments [2] - OmnifyXR aims to improve workflow efficiency, ergonomics, and visualization in interventional procedures [3] Technological Advancements - OmnifyXR allows for the creation of detailed 3D models in minutes without compromising sterility, enhancing procedural efficiency [4] - Recent technology expansions by GE HealthCare include the MINItrace Magni for PET tracers, Omni Legend PET/CT, and Clarify DL for improved imaging [7] Industry Prospects - The global interventional radiology market is projected to grow from $26.97 billion in 2024 to $42.34 billion by 2031, with a CAGR of 6.7%, driven by demand for minimally invasive procedures and advancements in imaging technology [5] - The successful implementation of OmnifyXR is expected to significantly boost GE HealthCare's global business [6] Recent Collaborations - GE HealthCare's collaboration with Medis Medical Imaging focuses on enhancing precision care for coronary artery disease through integration with the Allia Platform [8] - The introduction of SIGNA MAGNUS, a head-only MRI scanner, is pending FDA approval and aims to advance neuroscience research [9] Price Performance - GE HealthCare shares have increased by 1.4% over the past year, contrasting with a 25.3% decline in the industry and a 26.4% growth in the S&P 500 [10]